enGene Holdings Inc. Warrants

enGene Therapeutics Inc., through its subsidiary enGene, Inc., is a clinical-stage biotechnology company based in Montreal, Canada. It develops genetic medicines for patients with bladder cancer. Its lead product candidate, detalimogene voraplasmid, is a monotherapy for non-muscle invasive bladder cancer (NMIBC), and its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026.